Patient Access Program (PAP)

Patient Access Program (PAP)

Login

Username (Email)

Password

Register As Physician Forgot Your Password?

Home| Privacy| Contact us

Your are leaving merckpapanz.com.au

You have clicked on a link that will cause you to leave merckpapanz.com.au. The information you are about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information. Please confirm your action

On-Label Cost-Share Program Changes

Please note the Erbitux (cetuximab) on-label cost-share programs have changed for both Australia & New Zealand as of 1 February 2023. Please review the indications and total cap for your selected program before agreeing to the terms and conditions. Any questions please reach out to the Patient Services team as per the Contact Us tab.

Patient Access Programmes Moving

Merck Patient Access Programmes will be moving to a new site. This portal will be closed from 30th October 5pm AEDT. From 4^th November please visit www.pappx.com.au for the new patient access programmes portal.

Off Label Requests Notification

If your request is regarding the use of an unapproved product, a completed SAS Category A notification form/SAS Category B application pathway from the TGA is required before Merck can legally supply the product. As a part of the application process, you will be required to upload the SAS notification form or approval letter when you submit a patient specific request for an unapproved product. Click here for further details: https://www.tga.gov.au/form/special-access-scheme.